NASDAQ · CMND
Healthcare · Biotechnology
$6.14
Down-$0.08 (-1.29%)
Updated Nov 3, 2026, 3:19 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CMND
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
CMND closed at $6.14 after 21 trading sessions, up 2.33% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $6.02 | $6.14 | $6.01 | $6.14 | 1.93K |
| Oct 30, 2026 | $5.83 | $6.4986 | $5.80 | $6.2189 | 10.47K |
| Oct 29, 2026 | $6.15 | $6.1659 | $5.85 | $5.85 | 4.36K |
| Oct 28, 2026 | $5.9766 | $6.15 | $5.9766 | $6.06 | 5.03K |
| Oct 27, 2026 | $6.095 | $6.095 | $5.9476 | $5.9673 | 5.5K |
| Oct 26, 2026 | $5.92 | $6.20 | $5.8598 | $6.1214 | 16.36K |
| Oct 23, 2026 | $6.255 | $6.255 | $5.87 | $5.87 | 8.42K |
| Oct 22, 2026 | $6.01 | $6.095 | $6.00 | $6.00 | 5.3K |
| Oct 21, 2026 | $6.2525 | $6.2525 | $5.92 | $5.94 | 5.33K |
| Oct 20, 2026 | $5.9706 | $6.19 | $5.91 | $6.12 | 7K |
| Oct 19, 2026 | $6.1638 | $6.362 | $5.91 | $6.00 | 8.31K |
| Oct 16, 2026 | $6.33 | $6.47 | $6.2601 | $6.2601 | 4.14K |
| Oct 15, 2026 | $6.24 | $6.79 | $6.24 | $6.42 | 5.68K |
| Oct 14, 2026 | $6.36 | $6.47 | $6.20 | $6.2889 | 10.81K |
| Oct 13, 2026 | $6.50 | $6.73 | $6.23 | $6.23 | 11.01K |
| Oct 12, 2026 | $6.52 | $6.80 | $6.4814 | $6.54 | 16.2K |
| Oct 9, 2026 | $6.77 | $6.9399 | $6.35 | $6.58 | 9.08K |
| Oct 8, 2026 | $6.64 | $7.16 | $6.40 | $6.60 | 41.12K |
| Oct 7, 2026 | $5.75 | $6.70 | $5.54 | $6.60 | 147.08K |
| Oct 6, 2026 | $5.89 | $6.1746 | $5.701 | $5.84 | 35.37K |
| Oct 5, 2026 | $5.93 | $6.54 | $5.25 | $6.00 | 92.04K |
The latest Smart Investors Daily articles mentioning CMND.
Company
Market Activity
Research & News
CMND research
Company profile and research snapshot.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Oct 30, 2026
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity Therapeutics
Yahoo · Oct 28, 2026
For questions about this article or underlying research, email [email protected].
Yahoo · Oct 27, 2026
Milestone advances Clearmind’s clinical program as the company continues to develop CMND‑100 as a potential novel therapeutic candidate for alcohol use disorder Vancouver, Canada, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disord
Benzinga · Oct 27, 2026
Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CMND.
No results
No recent SID articles mention CMND.
